Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence, mitigation, and management of neurologic adverse events in the CARTITUDE-2 study of patients with multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel)
    Meeting Abstract

    Jakubowiak, A.; Parekh, S.; Madduri, D.; Santomasso, B.; Perez-Larraya, J. G.; van de Donk, N. W. C. J.; Arnulf, B.; Mateos, M. V.; De Braganca, K. C.; Varsos, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) exposed or refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies
    Meeting Abstract

    Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in 55 patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD): Subgroup analysis
    Meeting Abstract

    Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Updated experience from mosunetuzumab in multiple relapsed follicular lymphoma: Promising efficacy from a phase I trial
    Meeting Abstract

    Assouline, S.; Kim, W. S.; Sehn, L. H.; Schuster, S. J.; Cheah, C. Y.; Nastoupil, L. J.; Shadman, M.; Yoon, S. S.; Matasar, M. J.; Diefenbach, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma
    Meeting Abstract

    Iyer, S.; Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • CheckMate 436: Extended follow-up from the phase 2 study investigating nivolumab plus brentuximab vedotin (BV) for relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL)
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P.; Cunningham, D.; Kline, J.; Johnson, N.; Mehta-Shah, N.; Fanale, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Phase 1/2 BRUIN study results
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fahkri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Outcomes from the observational RE-MIND2 study
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Peters, A.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL)
    Meeting Abstract

    Ansell, S.; Bröckelmann, P.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G.; Cohen, J.; De Boer, J. P.; Kuruvilla, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for patients with previously untreated stage III/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study
    Meeting Abstract

    Ramchandren, R.; Długosz-Danecka, M.; Connors, J. M.; Radford, J.; Illés, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save